Abstract
Objectives The aim of this study was to estimate the prevalence and causes of vision impairment (VI) in Portugal.
Setting Information about people with VI was obtained from Primary Care Centres, blind association (ACAPO) and from hospitals (the PCVIP-study) in the Northwest of Portugal during a period spanning years 2014-2015. Causes of VI were obtained from hospitals.
Participants Administrative and medical records of people with visual acuity in the better seeing eye of 0.5 decimal (0.30logMAR) or worse and/or visual field less than 20 degrees were investigated. Capture-recapture with log-linear models was applied to estimate the number of individuals missing from lists of cases obtained from available sources.
Primary and secondary outcome measures Log-linear models were used to estimate the crude prevalence and the category specific prevalence of VI.
Results Crude prevalence of VI was 1.97% (95%CI=1.56-2.54), and standardized prevalence was 1% (95%CI=0.78-1.27). The age-specific prevalence was 3.27% (95% CI=2.36-4.90), older than 64 years, 0.64% (95%CI=0.49-0.88), aged 25-64 years, and 0.07% (95%CI=0.045-0.13), aged less than 25 years. The female-to-male ratio was1.3, that is, higher prevalence amongst females. The five leading causes of VI were Diabetic Retinopathy, Cataract, Age-related Macular Degeneration, Glaucoma and Disorders of the Globe.
Conclusions The prevalence of VI in Portugal was within the expected range and in line with other European countries. A significant number of cases of VI might be due to preventable cases and, therefore, a reduction of the prevalence of VI in Portugal seems possible. Women and old people were more likely to have VI and, therefore, these groups require extra attention. Future studies are necessary to characterize temporal changes in prevalence of VI in Portugal.
Strengths and limitations of this study
Medical records and registers of people with vision impairment were used to determine the number of cases in these sources.
Data from 3 sources (lists) with records about people with vision impairment were combined using log-linear models to determine the number of “uncaptured” cases.
Capture-recapture methods were used to determine the prevalence of vision impairment in the Northwest Portugal.
Capture-recapture methods to compute prevalence are more accurate than pure case counting from lists and more affordable than cross-sectional studies.
A limitation of the current study was the low completeness, that is, the number of cases captured compared with the number of uncaptured cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by FCT (COMPETE/QREN) grant reference PTDC/DPT-EPI/0412/2012 in the context of the Prevalence and Costs of Visual Impairment in Portugal: a hospital-based study (PCVIP-study). PLR is funded by FCT (COMPETE/QREN) grant reference SFRH/BD/119420/2016. AFM if founded by the faculty of Health and Life Sciences at Linnaeus University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the tenets of the Declaration of Helsinki, approved by the local ethics committees of the participating hospitals and by the ethical committee for Life Sciences and Health of the University of Minho, Ref. SECVS-084/2013; data protection process numbers 9936/2013 and 9793/ 2017.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
pedro.limaramos{at}lnu.se
ruisantana{at}ensp.unl.pt
patricia.marques{at}lshtm.ac.uk
isousa{at}math.uminho.pt
arsousa{at}med.up.pt
antonio.macedo{at}lnu.se; a.macedo{at}ucl.ac.uk
Ethics The study was conducted in accordance with the tenets of the Declaration of Helsinki, approved by the local ethics committees of the participating hospitals and by the ethical committee for Life Sciences and Health of the University of Minho, Ref. SECVS-084/2013; data protection process numbers 9936/2013 and 9793/ 2017. The authors only had access to anonymized, mostly administrative, information provided by authorized staff from the different institutions, for this purpose it was considered that there was no need to obtain signed consent form.
We have now changed the title and the manuscript to restrict our findings to the target region where the study was performed. We have now improved the description of the model used in methods sub-section "Application of the CR method". We also added information about internal validity of the model below Table 3 and in discussion below Table 5.
Data Availability
Upon request from the corresponding author
